Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SATRALIZUMAB-MWGE: 1,112 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
1,112
Total FAERS Reports
54 (4.9%)
Deaths Reported
398
Hospitalizations
1,112
As Primary/Secondary Suspect
20
Life-Threatening
21
Disabilities

First Report: 20080101 · Latest Report: 20250821

What Are the Most Common SATRALIZUMAB-MWGE Side Effects?

#1 Most Reported
Neuromyelitis optica spectrum disorder
181 reports (16.3%)
#2 Most Reported
Urinary tract infection
87 reports (7.8%)
#3 Most Reported
Off label use
87 reports (7.8%)

All SATRALIZUMAB-MWGE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Neuromyelitis optica spectrum disorder 181 16.3% 3 67
Off label use 87 7.8% 2 37
Urinary tract infection 87 7.8% 3 58
Pneumonia 64 5.8% 4 54
Covid-19 47 4.2% 5 25
No adverse event 47 4.2% 0 0
Fatigue 41 3.7% 0 10
Headache 36 3.2% 1 10
Pain 36 3.2% 0 15
Arthralgia 31 2.8% 0 5
Hypoaesthesia 30 2.7% 0 11
Nausea 27 2.4% 0 8
Sepsis 24 2.2% 3 21
Pyrexia 23 2.1% 1 11
Asthenia 22 2.0% 2 11
Fall 22 2.0% 3 11
Product dose omission issue 22 2.0% 0 4
Infection 21 1.9% 2 13
Malaise 20 1.8% 0 9
Gait disturbance 19 1.7% 1 4

Who Reports SATRALIZUMAB-MWGE Side Effects? Age & Gender Data

Gender: 86.4% female, 13.6% male. Average age: 56.3 years. Most reports from: US. View detailed demographics →

Is SATRALIZUMAB-MWGE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2008 2 0 2
2014 1 0 0
2015 2 0 2
2016 2 0 1
2017 3 0 3
2018 1 0 0
2019 3 0 1
2020 18 0 3
2021 81 5 42
2022 117 5 48
2023 140 12 55
2024 150 8 80
2025 82 6 50

View full timeline →

What Is SATRALIZUMAB-MWGE Used For?

IndicationReports
Neuromyelitis optica spectrum disorder 994
Product used for unknown indication 84
Demyelination 15
Myelitis 11
Multiple sclerosis 7
Myelin oligodendrocyte glycoprotein antibody-associated disease 5

SATRALIZUMAB-MWGE vs Alternatives: Which Is Safer?

SATRALIZUMAB-MWGE vs SAXAGLIPTIN SATRALIZUMAB-MWGE vs SCHOLL'S INGROWN TOENAIL PAIN RELIEVER SATRALIZUMAB-MWGE vs SCOPOLAMINE SATRALIZUMAB-MWGE vs SCOPOLAMINE HYDROBROMIDE SATRALIZUMAB-MWGE vs SEBELIPASE ALFA SATRALIZUMAB-MWGE vs SECNIDAZOLE SATRALIZUMAB-MWGE vs SECUKINUMAB SATRALIZUMAB-MWGE vs SELADELPAR LYSINE SATRALIZUMAB-MWGE vs SELEGILINE SATRALIZUMAB-MWGE vs SELENIUM

Official FDA Label for SATRALIZUMAB-MWGE

Official prescribing information from the FDA-approved drug label.